Novo Nordisk Drug Pipeline
To find information on the diseases treated and drug advancements for each of the target drugs. The drugs to be researched will include phase 3 drugs i.e. semaglutide, concizumab, & somapacitan and filed drugs i.e. oral semaglutide.
Phase 3 Drugs
- Semaglutide is a once per week injection that was approved in 2017 for the treatment of type 2 diabetes.
- The results of a phase 2 trial reported that the drug helped 65% of adults loose at least 10% of their body weight over 52 weeks.
Proposed next steps:
You need to be the project owner to select a next step.